Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 266-235-8 | CAS number: 66204-44-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Sept.24, 2001 to Dec. 17, 2002
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 3,3'-methylenebis[5-methyloxazolidine]
- EC Number:
- 266-235-8
- EC Name:
- 3,3'-methylenebis[5-methyloxazolidine]
- Cas Number:
- 66204-44-2
- Molecular formula:
- C9H18N2O2
- IUPAC Name:
- 3,3'-methylenebis[5-methyloxazolidine]
- Details on test material:
- - Name of test material (as cited in study report): 3,3'-methylenebis[5-methyl-oxazolidine]
- Substance type: Formaldehyde releaser
- Physical state: Clear, colourless liquid
- Analytical purity: content of formaldehyde 42.28%,
- Composition of test material, percentage of components: Reaction product from paraformaldehyde and 2 hydroxypropylamine (ratio of 3:2)
- Purity test date:
- Lot/batch No.: 24773
- Expiration date of the lot/batch: No data
-- Stability under test conditions: Stability was proven analytically
- Storage condition of test material: At room temperatur in tightly closed original container
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, D-97633 Sulzfeld
- Age at study initiation: At 1st dose: m 32 days, f 34 days
- Weight at study initiation: m 82-92 g and f 80-90 g upon receipt.
- Fasting period before study: no
- Housing: Single in Macrolon Type III cages
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +- 3
- Humidity (%): 5 +- 15
- Photoperiod (12 hrs dark / 12 hrs light):
IN-LIFE DATES: From January 10, 2002 to April 10, 2002
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was suspended in corn oil to the appropriate dose levels
VEHICLE
- Justification for use and choice of vehicle (if other than water): The test item forms a homogeneous suspension in corn oil
- Concentration in vehicle: 0, 4, 12, 36/24 mg/mL (0, 0.4, 1.2, 3.6/2.4%)
- Amount of vehicle (if gavage): 5 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration and stability of the test substance in dose solutions were tested in 3 samples per dose level. 0, 8, or 24 h after preparation the analytical concentration was max. 6.1% below the nominal concentration of the test substance at 0 h.
Homogeneity of the test substance during application period was tested on three samples per dose level; the variation was < 2%.
Samples at termination (last application to the last animal of each group) revealed analytical values resulting in 94.6-96.2% of nominal values.
Accuracy, precision, and sensitivity of the analytical method have been shown. - Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Once daily, 7 days per week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 20, 60, 180/120 mg/kg bw; high dose level reduced to 120 mg/kg bw at the end of week 12 due to increased mortality.
Basis:
actual ingested
- No. of animals per sex per dose:
- 10 m and 10 f per dose level
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected after a preliminary 28-Day dose range finding study (LPT Report 14814/01, dated January 09, 2002).
- Rationale for selecting satellite groups: No satellite groups included - Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least once daily each rat was observed for clinical signs, additionally immediately after each oral application. Mortality was checked twice daily and premortal symptoms recorded.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Detailed clinical observations were made in all animals once a week starting before the 1st application in a standard arena and included changes in skin, mucous membranes, autonomic activity, gait, posture, response to handling, as well the presence of abnormal secretions, abnormal movements or behaviour. At week 13 these observations were performed prior to any laboratory test.
BODY WEIGHT: Yes
- Time schedule for examinations: Measured once weekly starting day 0.
FOOD CONSUMPTION :
Calculated for each treatment week by the total amount of food given to and left by each rat in this week.
FOOD EFFICIANCY
No data
WATER CONSUMPTION
- Time schedule for examinations: Monitored daily.
OPHTHALMOSCOPIC EXAMINATION: Yes
Complete examination performed before exposure starts and prior to termination in all groups including recovery groups
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At day 90
- Anaesthetic used for blood collection: Yes :light ether anesthesia
- Animals fasted: Yes, overnight prior to sampling
- How many animals: All surviving animals per group and sex
- Parameters checked: Haematocrit, haemoglobin concentration, erythrocyte count, total and differential leukocyte count, platelet count, activated partial thromboplastin time, thromboplastin time.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At day 90
- Animals fasted: Yes, overnight prior to sampling
- How many animals: All surviving animals per group and sex
- Parameters checked: Sodium, potassium, glucose, total cholesterol, urea, creatinine, total protein, albumin, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (aP).
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: At the end of the exposure period (>= week 11) functional observations were recorded including sensory reactivity to different types of stimuli (auditory, visual, proprioreceptive), assessment of grip strength and motor activity.
- Dose groups that were examined: all - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Necropsy of rats in all 4 groups performed.
HISTOPATHOLOGY: Yes
All organs which are listed in the OECD guideline 408 were fixed in
formalin. Histopathological examinations of these organs were done in
tissues of controls and animals of the high dose group including animals
which died during the exposure period.
Due to substance related changes also stomach and bone marrow of low
and mid dose rats were examined histopathologically - Other examinations:
- Organ weights: The organ weights of liver, kidneys, adrenals, testes, epididymis, uterus, ovaries, thymus, spleen, brain, heart were determined before fixation. Same procedure with animals which died during exposure period but these data were not included in mean value comparison.
- Statistics:
- Suitable statistical methods were used and the level of significance was p<0.01 except in histopathology (p<0.05; Fisher exact test).
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- No treatment related effects were observed in the low and mid dose
groups. In the high dose group all males and females showed longlasting
piloerection from day 35 onwards. Ataxia was noted in one
female.
Functional observation battery
No treatment related effects were recorded in low and mid dose groups
at week 13. Reduced pupil size was detected in 3/7 male and 5/5 female
survivors. Further parameters were within the normal range. - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- No mortality in low and mid dose groups. High dose group: 3 males
died between day 49 and 75 and 5 females between day 49 and 79. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- No effect on body weight gain was detected in the low and mid dose
group. From test week 5 onwards the body weight of males in the high
dose group was decreased. The difference to controls was -10 to -21%
(p<0.01). Less decreased body weights were measured in females. The
difference to controls was -6 to -18% (p<0.01 at week 10). - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Transient effects on food consumption were measured in all treatment
groups. Significant decreases as well as increases were observed. No
dose dependency was detected. It was concluded by the authors that the
food consumption was not influenced by the test substance treatment. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- by visual appraisal
- Ophthalmological findings:
- effects observed, non-treatment-related
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance related changes were presented in the Table below. No
effects were recorded at 20 mg/kg bw. In males of the mid dose group
an increase in leucocyte counts was demonstrated as well as a decrease
in activated partial thromboplastin time (aPTT) (but no significant effect
at the high dose level, no dose dependency). The thromboplastin time
(TPT) was decreased in males of all three dose groups but this effect
was not considered to be treatment related since the concurrent control
value was high in comparison to historical controls (data not shown by
the authors).
Males and females of the high dose group revealed an increase in the
incidence of neutrophilic granulocytes and a decrease in lymphocytes.
Effects on leucocyte counts and alteration in differential blood count are
suggested by the authors to be treatment related and a consequence of
the lesions detected in the stomach. - Clinical biochemistry findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- No effects on relative or absolute organ weights were detected in the
low and mid dose groups.
Survivors at 180/120 mg/kg bw: Significant increase (p<0.01) in relative
organ weight was measured for the following organs: brain (+20% in
males and +17% in females), gonads (+23% [left] and +18% [right] in
males), and liver (+24% in females).
The absolute organ weights in females were not altered but in males the
absolute weights of the kidney (left -20%, right -23%), spleen (-23%),
thymus (-35%), epididymis (left -21%, right -17%) were decreased (no
data on statistical significance).
The toxicological relevance of these effects was not discussed by the
authors. However, it is suggested that the increase in relative weights of
brain and gonads are related to the decrease in body weight and/or to
increased metabolism concerning the liver. Furthermore, no
histopathological changes were noted. The decreases of the absolute
organ weights in males are also of low toxicological relevance since the
body weight also decreases. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 20 mg/kg bw: No treatment related effects were recorded in the low
dose group.
60 mg/kg bw: In females no pathological alterations were reported. In 5
out of 10 males greenish discolorations/nodules were observed in the
stomach.
180/120 mg/kg bw: Greenish, brown-blackish or reddish discolorations/
nodules in the stomach of 8/10 males and 6/10 females. Inflated,
enlarged, or reddish discoloured intestinal tract was detected in 2/10
males and 3/10 females. Reduced size of the thymus (1/10 males and
1/10 females) and spleen (1/10 males and 1/10 females) were reported. - Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- 20 mg/kg bw: The treatment did not induce any histopathological
alterations in the 2 organs examined in this group (stomach and bone
marrow).
60 mg/kg bw: Local effects in the stomach (see Table below) and
granulocytopoesis in bone marrow (inflammatory response) were
observed. Only these 2 organs were investigated.
180/120 mg/kg bw: Treatment related histopathological effects seen only in the stomach and bone marrow (see Table below). Further
changes in various organs were within the normal control range for
animals of this strain and age.
Authors comment: chronic ulcerative gastritis and peritonitis and/or
hyperplastic-hyperceratototic epithelial reactions with bacterial infection
especially of the proventricular part of the stomach in 6 males and 5
females of the mid dose group and all males and 9 females of the high
dose group.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- >= 20 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: overall effects
- Dose descriptor:
- LOAEL
- Effect level:
- >= 60 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: local effects to the stomach
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Altered parameters in haematology
|
Dose in mg/kg bw |
|||
Parameter |
0 |
20 |
60 |
180/120 |
|
Males |
|||
Leucocyte counts (106/ml) |
10.3+-2.15 |
12.8+-1.58 |
15.5+-3.01* |
11.1+-3.23 |
aPTT (sec) |
12.6+-1.09 |
11.7+-0.91 |
10.8+-1.39* |
11.2+-1.64 |
TPT (sec) |
9.3+-0.39 |
7.9+-0.48* |
8.0+-0.68* |
7.8+-0.21* |
Neutrophilic granulocytes (%) |
16.4 |
12.7 |
19.7 |
22.6 |
Lymphocytes (%) |
79.0 |
82.9 |
75.7 |
73.7 |
|
Females |
|||
Neutrophilic granulocytes (%) |
11.3 |
9.5 |
13.7 |
33.3 |
Lymphocytes (%) |
84.7 |
86.9 |
82.0 |
62.6 |
*: significant at p<0.01; mean ± standard deviation |
Table 2: Altered parameters in clinical chemistry of female rats
|
Dose in mg/kg bw |
|||
Parameter |
0 |
20 |
60 |
180/120 |
Albumin (mg/ml) |
39.3+-2.23 |
40.4+-3.21 |
39.9+-3.52 |
34.3+-4.01* |
Protein (mg/ml) |
75.4+-3.5 |
77.6+-4.6 |
76.9+-3.7 |
68.4+-8.4* |
*: significant at p<0.01; mean ± standard deviation |
Table 3: Treatment related
incidences of histopathological alterations
Data on terminal sacrifice
reported
|
Dose in mg/kg bw |
|||
Organ |
0 |
20 |
60 |
180/120 |
Stomach |
6/10 // 2/10 |
3/10 // 2/10 |
3/10 // 3/10 |
0/7* // 0/5 |
Submucosal lymphocytic hyperplasia |
0/10 // 0/10 |
0/10 // 0/10 |
0/10 // 0/10 |
3/7 // 3/5* |
Subepithelial mixed cell infiltration |
0/10 // 0/10 |
0/10 // 0/10 |
1/10 // 5/10* |
0/7 // 0/5 |
Epithelial hyperplasia |
0/10 // 0/10 |
0/10 // 0/10 |
1/10 // 4/10 |
0/7 // 0/5 |
Chronic ulcerative gastritis & peritonitis |
0/10 // 0/10 |
0/10 // 0/10 |
5/10* // 4/10 |
7/7** // 5/5** |
Bone marrow |
0/10 // 0/10 |
0/10 // 0/10 |
4/10 // 1/10 |
4/7* // 1/5 |
*: significant at p<0.05; **: at p<0.001; |
Applicant's summary and conclusion
- Conclusions:
- At dose level of ≥ 60 mg/kg bw and a concentration of ≥ 12 mg/mL in corn oil the test substance induced local effects in the stomach after repeated administration via gavage (LOAEL). Presumably higher LOAELs can be expected if the test substance is applied via drinking water or diet and not via gavage (bolus effect).
No effects were observed at a daily dose of 20 mg/kg bw. (NOAEL) - Executive summary:
The study was conducted according to OECD guideline 408 (adopted21stSept. 1998). Ten male and 10 female rats per dose level were gavaged once daily, 7 days per week for 90 days with 0, 20, 60, 180/120 mg/kg bw (concentration: 0, 0.4, 1.2, 3.6/2.4% in corn oil).
The test substance induced local effects in the stomach at a dose level of ≥ 60 mg/kg bw. Other reported effects like piloerection and reduced body weight gain in the high dose groups and alteration in haematology like increased leucocyte counts and shift in the differential blood count at mid and high dose level are considered to be a consequence of the chronic ulcerative gastritis & peritonitis. The reduced pupil size detected in males and females and altered clinical chemistry parameters in females of the high dose group are recognized but the toxicological relevance is unclear.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.